- Conditions
- Thyroid Eye Disease, Graves' Orbitopathy
- Interventions
- Teprotumumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Miami, Florida • Skokie, Illinois + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 81
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Thyroid Eye Disease
- Interventions
- Veligrotug
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Inglewood, California • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Graves' Disease
- Interventions
- IMVT-1402, Placebo
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 64
- States / cities
- Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 53 more
- Conditions
- Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
- Interventions
- linsitinib
- Drug
- Lead sponsor
- Sling Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Miami, Florida • Morgantown, West Virginia
- Conditions
- Thyroid Eye Disease
- Interventions
- Teprotumumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Los Angeles, California • Palo Alto, California + 4 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Teprotumumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Los Angeles, California • Miami, Florida + 5 more
- Conditions
- Graves Disease, Hyperthyroidism/Thyrotoxicosis
- Interventions
- Heart rate-based AI software for detecting thyrotoxicosis
- Device
- Lead sponsor
- THYROSCOPE INC.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Graves Disease, Graves' Disease, Hyperthyroidism
- Interventions
- Ergocalciferol 50,000 IU, Methimazole
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Thyroid Eye Disease
- Interventions
- TOUR006 - 20 MG, Placebo, TOUR006 - 50 MG
- Drug · Other
- Lead sponsor
- Tourmaline Bio, Inc., a Novartis Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Pasadena, California • Sacramento, California + 12 more
- Conditions
- Type 1 Diabetes, Hashimoto Disease, Graves Disease, Addison Disease, Autoimmune Polyglandular Syndrome Type III, Depression, Endocrine System Diseases
- Interventions
- Telehealth Resource Oriented Music Therapy
- Behavioral
- Lead sponsor
- Appalachian State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Boone, North Carolina
- Conditions
- Graves' Disease, Graves Disease
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 18
- States / cities
- Orange, California • Pasadena, California • Fleming Island, Florida + 14 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Veligrotug
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Newport Beach, California • Palo Alto, California + 13 more
- Conditions
- Bioavailability, Bioequivalence
- Interventions
- TEPEZZA, EDP
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
- Interventions
- TEPEZZA, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Thyroid Eye Disease
- Interventions
- SENSIMED Triggerfish
- Device
- Lead sponsor
- Sensimed AG
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Thyroid Eye Disease
- Interventions
- Celecoxib, artificial tears
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- Teprotumumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Graves Ophthalmopathy
- Interventions
- Bimatoprost Ophthalmic
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2031
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Graves' Disease
- Interventions
- CFZ533
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Honolulu, Hawaii • Rochester, Minnesota
- Conditions
- Thyroid Eye Disease
- Interventions
- Teprotumumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Miami, Florida • St Louis, Missouri • Bellaire, Texas
- Conditions
- Graves Disease
- Interventions
- Methimazole Tablets
- Drug
- Lead sponsor
- Cook County Health
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Thyroid Eye Disease
- Interventions
- lonigutamab, Placebo
- Drug
- Lead sponsor
- ACELYRIN Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more
- Conditions
- Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
- Interventions
- teprotumumab, normal saline
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
- Conditions
- Thyroid Eye Disease, TED
- Interventions
- focus groups and individual interviews as well as filling out questionnaires
- Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania